Which class is considered first-line treatment for depression?

Which class is considered first-line treatment for depression?

• A. MAO inhibitors
• B. Tricyclic antidepressants
• C. SSRIs
• D. Atypical antidepressants

Answer: (C)

First-line treatment for depression prioritizes an option with solid efficacy and a favorable safety and tolerability profile for most patients. Selective serotonin reuptake inhibitors fit that goal because they increase serotonin in the brain by blocking its reuptake, yet they tend to cause fewer and less severe side effects than older antidepressants. They have notably lower risk of lethal overdose compared with tricyclics, and they don’t require the dietary restrictions that come with monoamine oxidase inhibitors. This combination of effectiveness, safety, and easier use makes them the typical starting choice. Of course, they can cause side effects like nausea, sleep disturbances, and sexual dysfunction, and there’s a need to watch for serotonin syndrome if combined with other serotonergic drugs. Other classes carry greater safety concerns or restrictions (overdose risk with TCAs, dietary and drug interaction issues with MAO inhibitors, or use as alternatives in specific situations with atypicals), which is why they aren’t the default first option.

First-line treatment for depression prioritizes an option with solid efficacy and a favorable safety and tolerability profile for most patients. Selective serotonin reuptake inhibitors fit that goal because they increase serotonin in the brain by blocking its reuptake, yet they tend to cause fewer and less severe side effects than older antidepressants. They have notably lower risk of lethal overdose compared with tricyclics, and they don’t require the dietary restrictions that come with monoamine oxidase inhibitors. This combination of effectiveness, safety, and easier use makes them the typical starting choice. Of course, they can cause side effects like nausea, sleep disturbances, and sexual dysfunction, and there’s a need to watch for serotonin syndrome if combined with other serotonergic drugs. Other classes carry greater safety concerns or restrictions (overdose risk with TCAs, dietary and drug interaction issues with MAO inhibitors, or use as alternatives in specific situations with atypicals), which is why they aren’t the default first option.